FIELD: biotechnology.
SUBSTANCE: group of inventions relates to a constructed immune cell, where the specified immune cell is selected from T cells, NK cells, and their precursors, which is defective by Suv39h1, and to its use. In addition, a method for the production of a genetically constructed immune cell defective by Suv39h1 is presented, where the method includes a stage of inhibition of expression and/or activity of Suv39h1 in T cell, NK cell, or their precursor, so that the resulting constructed T cell, NK cell, or their precursor have increased survival rate. A pharmaceutical composition for adoptive cell therapy is also disclosed, containing at least one constructed cell defective by Suv39h1.
EFFECT: invention allows for its use in adoptive therapy, first of all for the effective treatment of cancer.
25 cl, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY | 2012 |
|
RU2688185C2 |
| USE OF THE ANTI-O-ACETYLATED GANGLIOSIDE GD2 ANTIBODY FOR IMPROVING THE THERAPEUTIC POTENTIAL OF DRUGS | 2017 |
|
RU2771173C2 |
| PRODUCTION OF CONSTRUCTED CELLS FOR ADOPTIVE CELL THERAPY | 2017 |
|
RU2780156C2 |
| CHIMERIC RECEPTORS CONTAINING TRAF-6-INDUCING DOMAINS AND COMPOSITIONS AND METHODS RELATED TO THEM | 2016 |
|
RU2773159C2 |
| METHODS OF EX VIVO EXPANSION OF NATURAL KILLER CELLS AND THEIR USE | 2019 |
|
RU2814083C2 |
| CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COSTIMULATION DOMAINS | 2018 |
|
RU2800922C2 |
| MULTI-CHAIN CHIMERIC ANTIGEN RECEPTOR AND USES THEREOF | 2013 |
|
RU2663725C2 |
| METHODS OF EXPANSION OF ANTIGEN-SPECIFIC CAR-T-CELLS, COMPOSITIONS AND THEIR USE | 2019 |
|
RU2800920C2 |
| CELL TARGETING MEDIATED BY CHIMERIC ANTIGEN RECEPTOR | 2018 |
|
RU2783316C2 |
| METHODS AND COMPOSITIONS FOR OBTAINING GENETICALLY ENGINEERED CELLS | 2018 |
|
RU2795454C2 |
